RPE65 and respiratory distress syndrome in premature infants: An example of the successful application of AAV in retinal gene therapy is the FDA-approved treatment of IRDs associated with RPE65 mutations, using AAV2 capsids to deliver a therapeutic cassette containing a functional copy of hRPE65 (Luxturna, Spark Therapeutics, Philadelphia, PA, USA; 2017, AAV2/2.ssAAV transgene).